ZA200809773B - Galenical formulations of aliskiren and hydrochlorothiazide - Google Patents

Galenical formulations of aliskiren and hydrochlorothiazide

Info

Publication number
ZA200809773B
ZA200809773B ZA200809773A ZA200809773A ZA200809773B ZA 200809773 B ZA200809773 B ZA 200809773B ZA 200809773 A ZA200809773 A ZA 200809773A ZA 200809773 A ZA200809773 A ZA 200809773A ZA 200809773 B ZA200809773 B ZA 200809773B
Authority
ZA
South Africa
Prior art keywords
aliskiren
hydrochlorothiazide
galenical formulations
galenical
formulations
Prior art date
Application number
ZA200809773A
Other languages
English (en)
Inventor
Willmann Matthias
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36803824&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200809773(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ZA200809773B publication Critical patent/ZA200809773B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA200809773A 2006-06-23 2008-11-17 Galenical formulations of aliskiren and hydrochlorothiazide ZA200809773B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0612540.5A GB0612540D0 (en) 2006-06-23 2006-06-23 Galenical formulations of organic compounds

Publications (1)

Publication Number Publication Date
ZA200809773B true ZA200809773B (en) 2009-11-25

Family

ID=36803824

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200809773A ZA200809773B (en) 2006-06-23 2008-11-17 Galenical formulations of aliskiren and hydrochlorothiazide

Country Status (26)

Country Link
US (1) US8618172B2 (pt)
EP (3) EP2311439A1 (pt)
JP (1) JP5362556B2 (pt)
KR (1) KR101442272B1 (pt)
CN (1) CN101472566A (pt)
AR (1) AR061565A1 (pt)
AU (1) AU2007263261B2 (pt)
BR (1) BRPI0713338A2 (pt)
CA (1) CA2654872A1 (pt)
CL (1) CL2007001837A1 (pt)
EC (1) ECSP088986A (pt)
ES (1) ES2704979T3 (pt)
GB (1) GB0612540D0 (pt)
GT (1) GT200800297A (pt)
IL (1) IL195425A (pt)
MA (1) MA30527B1 (pt)
MX (1) MX2008016533A (pt)
MY (1) MY146779A (pt)
NO (1) NO20090262L (pt)
NZ (1) NZ572937A (pt)
PE (2) PE20120990A1 (pt)
RU (1) RU2491058C2 (pt)
TN (1) TNSN08528A1 (pt)
TW (1) TWI457137B (pt)
WO (1) WO2007147596A1 (pt)
ZA (1) ZA200809773B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20091203A1 (es) * 2007-09-28 2009-09-11 Novartis Ag Composiciones farmaceuticas que comprende alisquireno o una sal farmaceuticamente aceptable del mismo
EP2143425A1 (de) * 2008-07-11 2010-01-13 Ratiopharm GmbH Direktverpresste Aliskiren-Tabletten
JP2010031006A (ja) * 2008-07-17 2010-02-12 Novartis Ag 有機化合物の使用
ES2365429B1 (es) 2010-03-05 2012-09-06 Universidad De Castilla De La Mancha Solucion para dialisis peritoneal
CN102626391B (zh) * 2012-04-19 2013-07-10 海南美兰史克制药有限公司 一种阿利克仑氢氯噻嗪药物组合物脂质体固体制剂
PL2968182T3 (pl) * 2013-03-15 2018-10-31 SpecGx, LLC Zniechęcająca do nadużywania stała postać dawkowania dla natychmiastowego uwalniania z funkcjonalnym rowkiem

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY119161A (en) 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
TW442301B (en) * 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
TW506836B (en) * 1996-06-14 2002-10-21 Janssen Pharmaceutica Nv Fast-dissolving galanthamine hydrobromide tablet
GB9613470D0 (en) 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
US6010719A (en) 1997-09-16 2000-01-04 Universiteit Gent Freeze-dried disintegrating tablets
PE20001302A1 (es) * 1998-11-27 2000-11-30 Hoffmann La Roche Preparaciones de una combinacion farmaceutica que contiene carvedilol e hidroclorotiazida
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
IS1935B (is) * 2002-03-19 2004-06-16 Actavis Group Hf. Fósínópríl lyfjasamsetning
BR0310084A (pt) * 2002-05-17 2005-02-15 Novartis Ag Composição farmacêutica compreendendo um inibidor de renina, um bloqueador de canal de cálcio e um diurético
BG65538B1 (bg) * 2002-07-05 2008-11-28 "Софарма" Ад Лекарствена форма на силимарин и метод за нейнотополучаване
WO2005077418A1 (en) * 2004-02-17 2005-08-25 Novartis Ag Combination of renin inhibitor and diuretics
PE20142101A1 (es) 2004-03-17 2014-12-27 Novartis Ag Composiciones farmaceuticas de aliskiren
ATE493973T1 (de) * 2004-06-04 2011-01-15 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
WO2006041763A1 (en) * 2004-10-04 2006-04-20 Novartis Ag Renin inhibitors for treating transplantation induced diseases
US8367105B2 (en) * 2004-11-10 2013-02-05 Teva Pharmaceutical Industries, Ltd. Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
MY146830A (en) 2005-02-11 2012-09-28 Novartis Ag Combination of organic compounds
CN101166523A (zh) * 2005-04-27 2008-04-23 诺瓦提斯公司 治疗动脉粥样硬化的方法
RU2008119687A (ru) * 2005-10-21 2009-11-27 Новартис АГ (CH) Комбинации органических соединений

Also Published As

Publication number Publication date
GB0612540D0 (en) 2006-08-02
US8618172B2 (en) 2013-12-31
CL2007001837A1 (es) 2008-06-13
PE20120990A1 (es) 2012-08-16
BRPI0713338A2 (pt) 2012-03-06
KR101442272B1 (ko) 2014-09-22
PE20080373A1 (es) 2008-06-06
TWI457137B (zh) 2014-10-21
MA30527B1 (fr) 2009-06-01
MX2008016533A (es) 2009-01-19
EP2311439A1 (en) 2011-04-20
ES2704979T3 (es) 2019-03-21
AR061565A1 (es) 2008-09-03
NZ572937A (en) 2011-11-25
US20090203679A1 (en) 2009-08-13
RU2009101971A (ru) 2010-07-27
EP2034968B1 (en) 2018-10-31
TW200808358A (en) 2008-02-16
ECSP088986A (es) 2009-01-30
KR20090021353A (ko) 2009-03-03
CN101472566A (zh) 2009-07-01
GT200800297A (es) 2009-03-09
JP5362556B2 (ja) 2013-12-11
TNSN08528A1 (en) 2010-04-14
IL195425A0 (en) 2009-08-03
JP2009541239A (ja) 2009-11-26
NO20090262L (no) 2009-01-19
AU2007263261A1 (en) 2007-12-27
IL195425A (en) 2014-01-30
AU2007263261B2 (en) 2011-07-14
CA2654872A1 (en) 2007-12-27
RU2491058C2 (ru) 2013-08-27
WO2007147596A1 (en) 2007-12-27
EP3391878A1 (en) 2018-10-24
MY146779A (en) 2012-09-28
EP2034968A1 (en) 2009-03-18

Similar Documents

Publication Publication Date Title
HUS2100009I1 (hu) Halauxifen-metil és piroxszulam kombinációja
IL242883B (en) Aryl-amino and heteroaryl-amino converted deoxazolines and pharmaceutical preparations containing them
IL198513A0 (en) Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
IL189011A0 (en) COMPOSITIONS OF tRNA AND USES THEREOF
GB0624729D0 (en) Reversible micelles and applications for their use
IL192990A0 (en) Methods and compositions of targeted drug development
EP2203158A4 (en) PHARMACEUTICAL FORMULATIONS WITH TELMISARTAN AND HYDROCHLORTHIAZIDE
IL184563A (en) Pharmaceutical foam formulations and their use
EP2056835A4 (en) PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
IL219155A0 (en) Pharmaceutical formulations of nitrite and uses thereof
EP2046957A4 (en) DATURURASES OF FATTY ACIDS AND USES THEREOF
EP2046129A4 (en) HERBICIDE COMPOSITION AND METHOD OF USE
IL207724A0 (en) Cns pharmaceutical compositions and methods of use
EP2209750A4 (en) CEMENT FORMULATIONS AND PRODUCTS
EP2185112A4 (en) STABILIZED THERAPEUTIC COMPOSITIONS AND FORMULATIONS
IL196594A0 (en) Derivatives of 4-trimethylammonium-3-aminobutyrate and 4-trimethylphosphonium-3-aminobutyrate as cpt-inhibitors
EP2046128A4 (en) HERBICIDAL COMPOSITION AND METHOD FOR THEIR USE
IL195425A0 (en) Galenical formulations of aliskiren and hydrochlorothiazide
EP2046116A4 (en) HERBICIDE COMPOSITION AND METHOD OF USE
GB0610090D0 (en) Particulate drug compositions and their uses
IL197273A0 (en) Pharmaceutical and sunscreen compositions comprising caspase-14
GB0614365D0 (en) Pharmaceutical compositions and their use
EP1987868A4 (en) PROCESS FOR THE INDUSTRIAL USE OF TYROSOL AND HYDROXYTYROSOL CONTAINED IN THE SOLID BY-PRODUCTS OF INDUSTRIAL OLIVE PRESSURE
PL2572724T3 (pl) Leczenie zwłóknień i chorób wątroby
ZA201001144B (en) Galenical formulations of aliskiren